ECSP13012486A - DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZIN-5,8-DIONA - Google Patents
DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZIN-5,8-DIONAInfo
- Publication number
- ECSP13012486A ECSP13012486A ECSP13012486A ECSP13012486A EC SP13012486 A ECSP13012486 A EC SP13012486A EC SP13012486 A ECSP13012486 A EC SP13012486A EC SP13012486 A ECSP13012486 A EC SP13012486A
- Authority
- EC
- Ecuador
- Prior art keywords
- oxazolo
- pde
- pyrazin
- dihydro
- dione
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D503/02—Preparation
- C07D503/04—Preparation by forming the ring or condensed ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención describe una serie de derivados de 6,7-dihidro-3H-oxazolo[3,4-a]pirazin-5,8-diona, sus mezclas, sus sales farmacéuticamente aceptables, que son inhibidores de PDE-5, que poseen propiedades vasodilatadoras y efectos de relajación. En particular, el derivado (R)-3-(1,3-benzodioxol-5-il)-1-(1H-indol-3-il)-7-metil-6,7-dihidro[1,3]oxazolo[3,4-a]pirazin-5,8-diona, su enantiómero (S)-3-(1,3-benzodioxol-5-il)-1-(1H-indol-3-il)-7-metil-6,7-dihidro[1,3]oxazolo[3,4-a]pirazin-5,8-diona.La presente invención describe, además, procesos para la preparación de dichos compuestos, composiciones farmacéuticas que los contienen, así como usos como inhibidores de la enzima fosfodiesterasa de tipo 5 (PDE-5) en el tratamiento de te disfunción eréctil y trastornos tratables con inhibidor de PDE-5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37348310P | 2010-08-13 | 2010-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012486A true ECSP13012486A (es) | 2013-04-30 |
Family
ID=45023415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012486 ECSP13012486A (es) | 2010-08-13 | 2013-03-12 | DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZIN-5,8-DIONA |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8338432B2 (es) |
| EP (1) | EP2603512B1 (es) |
| JP (1) | JP5940535B2 (es) |
| KR (1) | KR101871856B1 (es) |
| CN (1) | CN103108878B (es) |
| AR (1) | AR082661A1 (es) |
| BR (1) | BR112013003225B1 (es) |
| CA (1) | CA2807872C (es) |
| CL (1) | CL2013000434A1 (es) |
| CO (1) | CO6680703A2 (es) |
| DK (1) | DK2603512T3 (es) |
| EC (1) | ECSP13012486A (es) |
| ES (1) | ES2565493T3 (es) |
| HU (1) | HUE027903T2 (es) |
| IL (1) | IL224683A (es) |
| MX (1) | MX347632B (es) |
| PL (1) | PL2603512T3 (es) |
| PY (1) | PY1132289A (es) |
| RU (1) | RU2581831C2 (es) |
| UY (1) | UY33535A (es) |
| WO (1) | WO2012019254A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY33535A (es) * | 2010-08-13 | 2011-12-01 | Biolab Sanus Farmaceutuca Limitada | Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona |
| AR099523A1 (es) * | 2014-02-24 | 2016-07-27 | Biolab Sanus Farmacêutica Ltda | Compuestos derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazina-5,8-diona |
| CN107074847A (zh) * | 2014-09-12 | 2017-08-18 | 生物实验萨纽斯药物有限公司 | 新的吡啶并嘧啶衍生物化合物 |
| JP2022540866A (ja) | 2019-07-15 | 2022-09-20 | バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー. | 3-(ベンゾ[d][1,3]ジオキサゾール-5-イル)-7-(1-ヒドロキシプロパン-2-イル)-1-(1H-インドール-3-イル)-6,7-ジヒドロ-3H-オキサゾール[3,4-a]ピラジン-5,8-ジオン化合物の立体異性体およびその抗腫瘍剤およびホスホジエステラーゼ酵素阻害剤としての使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4844396A (en) | 1995-03-01 | 1996-09-18 | Kyowa Hakko Kogyo Co. Ltd. | Imidazoquinazoline derivatives |
| GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| ES2307758T3 (es) * | 2001-06-05 | 2008-12-01 | Lilly Icos Llc | Derivados de pirazino (1',2':1,6)pirido(3,4-b)indol 1,4-diona. |
| DE60213798T2 (de) * | 2001-06-21 | 2007-08-16 | Lilly Icos Llc, Wilmington | Carbolinderivate als pdev inhibitoren |
| AR045950A1 (es) * | 2003-10-09 | 2005-11-16 | Speedel Experimenta Ag | Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos. |
| CA2562251C (en) | 2004-04-07 | 2009-04-28 | Pfizer Inc. | Pyrazolo'4,3-d pyrimidines |
| RU2418590C2 (ru) * | 2006-04-04 | 2011-05-20 | Донг-А Фарматех Ко. Лтд. | Средство для предупреждения и лечения гиперплазии предстательной железы, содержащее производное пиразолопиримидинона |
| BRPI0903803B1 (pt) * | 2009-09-30 | 2019-07-09 | Biolab Sanus Farmacêutica Ltda. | Composto, processo de preparação, composição farmacêutica e uso dos compostos |
| UY33535A (es) * | 2010-08-13 | 2011-12-01 | Biolab Sanus Farmaceutuca Limitada | Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona |
-
2011
- 2011-07-27 UY UY0001033535A patent/UY33535A/es active IP Right Grant
- 2011-08-02 HU HUE11815927A patent/HUE027903T2/hu unknown
- 2011-08-02 KR KR1020137006343A patent/KR101871856B1/ko active Active
- 2011-08-02 BR BR112013003225-1A patent/BR112013003225B1/pt active IP Right Grant
- 2011-08-02 WO PCT/BR2011/000255 patent/WO2012019254A1/en not_active Ceased
- 2011-08-02 JP JP2013523443A patent/JP5940535B2/ja active Active
- 2011-08-02 CA CA2807872A patent/CA2807872C/en active Active
- 2011-08-02 CN CN201180039626.8A patent/CN103108878B/zh active Active
- 2011-08-02 US US13/196,363 patent/US8338432B2/en active Active
- 2011-08-02 EP EP11815927.6A patent/EP2603512B1/en active Active
- 2011-08-02 MX MX2013001692A patent/MX347632B/es active IP Right Grant
- 2011-08-02 DK DK11815927.6T patent/DK2603512T3/en active
- 2011-08-02 ES ES11815927.6T patent/ES2565493T3/es active Active
- 2011-08-02 RU RU2013110795/04A patent/RU2581831C2/ru active
- 2011-08-02 PL PL11815927.6T patent/PL2603512T3/pl unknown
- 2011-08-03 PY PY201101132289A patent/PY1132289A/es unknown
- 2011-08-09 AR ARP110102892A patent/AR082661A1/es active IP Right Grant
-
2013
- 2013-02-12 IL IL224683A patent/IL224683A/en active IP Right Grant
- 2013-02-12 CL CL2013000434A patent/CL2013000434A1/es unknown
- 2013-03-08 CO CO13046988A patent/CO6680703A2/es active IP Right Grant
- 2013-03-12 EC ECSP13012486 patent/ECSP13012486A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012019254A1 (en) | 2012-02-16 |
| CO6680703A2 (es) | 2013-05-31 |
| PL2603512T3 (pl) | 2016-09-30 |
| CL2013000434A1 (es) | 2013-06-07 |
| DK2603512T3 (en) | 2016-04-04 |
| HK1184786A1 (zh) | 2014-01-30 |
| BR112013003225B1 (pt) | 2021-03-30 |
| MX2013001692A (es) | 2013-03-18 |
| UY33535A (es) | 2011-12-01 |
| EP2603512A1 (en) | 2013-06-19 |
| JP2013533290A (ja) | 2013-08-22 |
| EP2603512B1 (en) | 2015-12-30 |
| CA2807872A1 (en) | 2012-02-16 |
| HUE027903T2 (hu) | 2016-11-28 |
| BR112013003225A2 (pt) | 2016-06-07 |
| PY1132289A (es) | 2015-04-01 |
| ES2565493T3 (es) | 2016-04-05 |
| CN103108878A (zh) | 2013-05-15 |
| AR082661A1 (es) | 2012-12-26 |
| RU2013110795A (ru) | 2014-09-20 |
| US8338432B2 (en) | 2012-12-25 |
| MX347632B (es) | 2017-05-04 |
| US20120040988A1 (en) | 2012-02-16 |
| CN103108878B (zh) | 2016-01-27 |
| RU2581831C2 (ru) | 2016-04-20 |
| IL224683A (en) | 2016-03-31 |
| CA2807872C (en) | 2018-07-24 |
| EP2603512A4 (en) | 2014-07-16 |
| KR101871856B1 (ko) | 2018-06-28 |
| JP5940535B2 (ja) | 2016-06-29 |
| KR20130109110A (ko) | 2013-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19011216A (es) | Inhibidores de piridopyrimdinona cdk2/4/6 | |
| SV2010003621A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y p13 quinasa y su sintesis | |
| ECSP088906A (es) | PIRAZOLO 1,5-a PIRIMIDINAS | |
| CL2012002270A1 (es) | Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer. | |
| CO6602133A2 (es) | Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas | |
| CL2011003082A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa. | |
| CL2008003578A1 (es) | Compuestos derivados de imidazo[1,5-a]-quinoxalina, inhibidores pde10; composicion farmaceutica que los comprende y/o kit; procedimiento de preparacion de estos; y su uso en el tratamiento de enfermedades snc | |
| CU20120118A7 (es) | Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak | |
| CL2007001554A1 (es) | Compuestos derivados de pirido [3,2-e]pirazinas;inhibidoras de pde10;procedimiento de preparacion;composicion farmaceutica que comprende; kit farmaceutico; uso para preparar de un medicamento para tratar o prevenir trastornos asociados a la hiperactividad de pde10 y/o trastornos en los que inhibir la pde10 es de valor. | |
| PE20160588A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| CL2009000724A1 (es) | Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico. | |
| MX348290B (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton. | |
| NI201000060A (es) | COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA. | |
| CO2018005163A2 (es) | Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo | |
| CL2012000589A1 (es) | Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras. | |
| CL2012001027A1 (es) | Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek. | |
| CU20110158A7 (es) | Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata | |
| CL2009000957A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras. | |
| ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| ECSP19043790A (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de PDE1 | |
| ECSP10010389A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
| ECSP13012486A (es) | DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZIN-5,8-DIONA | |
| ECSP088441A (es) | Derivados de pirazolo [4,3-d]pirimidin-5-il usados como inhibidores de pde5 |